Nanobiotix (NASDAQ:NBTX) Shares Gap Down – What’s Next?

Posted by Brenda Bartman on Jul 15th, 2026

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX – Get Free Report)’s stock price gapped down before the market opened on Wednesday . The stock had previously closed at $41.64, but opened at $40.23. Nanobiotix shares last traded at $40.3590, with a volume of 8,484 shares changing hands.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Guggenheim upped their price objective on Nanobiotix from $26.00 to $36.00 and gave the stock a “buy” rating in a research note on Thursday, April 2nd. Leerink Partners lifted their target price on Nanobiotix from $37.00 to $46.00 and gave the company an “outperform” rating in a research note on Thursday, June 4th. HC Wainwright reissued a “buy” rating on shares of Nanobiotix in a report on Monday, May 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a research note on Tuesday, April 21st. Finally, UBS Group lifted their price objective on shares of Nanobiotix from $3.50 to $30.00 and gave the company a “neutral” rating in a research report on Friday, May 1st. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $37.33.

Read Our Latest Stock Analysis on Nanobiotix

Nanobiotix Stock Down 3.5%

The firm’s 50 day simple moving average is $39.95 and its 200 day simple moving average is $31.92.

Institutional Investors Weigh In On Nanobiotix

A number of hedge funds have recently made changes to their positions in NBTX. Millennium Management LLC bought a new position in Nanobiotix during the fourth quarter valued at approximately $390,000. Royal Bank of Canada increased its stake in Nanobiotix by 2,000.0% in the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after acquiring an additional 2,500 shares during the last quarter. Finally, Marshall Wace LLP bought a new stake in Nanobiotix in the 4th quarter worth approximately $220,000. 38.81% of the stock is currently owned by hedge funds and other institutional investors.

Nanobiotix Company Profile

(Get Free Report)

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.